Stoke Therapeutics Inc. (0GT)
XDUS
Real-time Data
06:00 AM
Day's Range
27.2252 wk Range
15.80Overview - 0GT - Stoke Therapeutics Inc.
Key Statistics
Valuation
P/E (Trailing)
‪-226.83‬
PEG Ratio
‪-1.71‬
Price / Book
‪5.20‬
Profitability
Operating Margin
‪-11.16%‬
Return on Assets
‪-1.64%‬
Return on Equity
‪-1.95%‬
Ownership
Shares Outstanding
62.40M
Price stats
50-Day Avg
‪26.56‬
200-Day Avg
‪26.97‬
Peers - 0GT - Stoke Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on XDUS.
- 0GTXDUSStoke Therapeutics Inc.+39.75%52-week change-226.83P/E (Trailing)—Profit Margin
- 4E2XDUSRelmada Therapeutics Inc.+85.50%52-week change-2.59P/E (Trailing)—Profit Margin
- 3920XDUSSpyre Therapeutics, Inc.+84.40%52-week change-45.96P/E (Trailing)—Profit Margin
- 42ZXDUSRevolution Medicines Inc.+82.81%52-week change-30.12P/E (Trailing)—Profit Margin
- 87EXDUSDianthus Therapeutics Inc.+78.08%52-week change-22.38P/E (Trailing)—Profit Margin
- 5NRXDUSNanobiotix S.A.+77.27%52-week change—P/E (Trailing)—Profit Margin
- 5NRAXDUSNanobiotix S.A. American Depositary Shares+77.03%52-week change—P/E (Trailing)—Profit Margin
Profile Summary - 0GT - Stoke Therapeutics Inc.
About
Stoke Therapeutics Inc. is a biotechnology company focused on developing RNA-based medicines to treat the underlying causes of severe genetic diseases. It employs its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) platform, which uses antisense oligonucleotides to upregulate protein expression from…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
